Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity

Journal of Clinical Investigation

Volumn 121, Issue 9, 2011, Pages 3609-3622

  Mamessier, Emilie ^a,f   Sylvain, Aude ^a   Thibult, Marie Laure ^a   Houvenaeghel, Gilles ^b   Jacquemier, Jocelyne ^b   Castellano, Rémy ^a   Gonçalves, Anthony ^b   André, Pascale ^c   Romagné, François ^c   Thibault, Gilles ^d   Viens, Patrice ^b   Birnbaum, Daniel ^a,b   Bertucci, François ^a,b   Moretta, Alessandro ^e   Olive, Daniel ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c INNATE PHARMA   (France)

^d UNIVERSITÉ DE TOURS   (France)

^e UNIVERSITY OF GENOA   (Italy)

^f CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN DNAM 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST; BREAST CANCER; CELL FUNCTION; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BREAST NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON-GAMMA; K562 CELLS; KILLER CELLS, NATURAL; MAMMARY GLANDS, HUMAN; MIDDLE AGED; NEOPLASM INVASIVENESS; RECEPTORS, NATURAL KILLER CELL; SELF TOLERANCE; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 80052346280     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI45816     Document Type: Article

References (88)

1. Tirona M.T., Sehgal R., Ballester O. Prevention of breast cancer (part I): Epidemiology, risk factors, and risk assessment tools. Cancer Invest. 2010;28(7):743-750.
2. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9(4):239-252.
3. Kute T.E., et al. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. Cancer Immunol Immunother. 2009;58(11):1887-1896.
4. Smyth M.J., Dunn G.P., Schreiber R.D. Cancer immunosurveillance and immunoediting: The roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1-50. (Pubitemid 43765795)
5. Shankaran V., et al. IFN-gamma and lymphocytes prevent primary tumor development and shape tumor immunogenicity. Nature. 2001; 410(6832):1107-1111. (Pubitemid 32391043)
6. Dewan M.Z., et al. Natural-killer-cells in breastcancer cell growth and metastasis in SCID mice. Biomed Pharmacother. 2005;59 suppl 2:S375-S379.
7. Dewan M.Z., et al. Role of Natural-killer-cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Res Treat. 2007;104(3):267-275.
8. Olkhanud P.B., et al. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res. 2009; 69(14):5996-6004.
9. Treilleux I., et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res. 2004;10(22):7466-7474. (Pubitemid 39561754)
10. Gobert M., et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009;69(5):2000-2009.
11. Caras I., et al. Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother. 2004;53(12):1146-1152. (Pubitemid 39506403)
12. Alexe G., et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res. 2007;67(22):10669-10676. (Pubitemid 350145892)
13. Bertucci F., et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 2006;66(9):4636-4644.
14. Finak G., et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14(5):518-527. (Pubitemid 351655218)
15. Sabatier R., et al. A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat. 2011;126(2):407-420.
16. Trinchieri G. Biology of Natural-killer-cells. Adv Immunol. 1989;47:187-376.
17. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of Natural-killer-cells. Nat Immunol. 2008;9(5):503-510.
18. Moretta L., Bottino C., Pende D., Vitale M., Mingari M.C., Moretta A. Different checkpoints in human NK-cell activation. Trends Immunol. 2004; 25(12):670-676. (Pubitemid 39457981)
19. Lanier L.L. NK cell receptors. Annu Rev Immunol. 1998;16:359-393. (Pubitemid 28183369)
20. Moretta A., et al. Activating receptors and coreceptors involved in human Natural-killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197-223. (Pubitemid 32368034)
21. Bauer S., et al. Activation of NK-cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285(5428):727-729.
22. Moretta L., Bottino C., Pende D., Castriconi R., Mingari M.C., Moretta A. Surface NK receptors and their ligands on tumor cells. Semin Immunol. 2006;18(3):151-158. (Pubitemid 43817561)
23. Moretta A., et al. Receptors for HLA-class I-molecules in human Natural-killer-cells. Annu Rev Immunol. 1996;14:619-648. (Pubitemid 26130196)
24. Moretta A., et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural-killer cells. J Exp Med. 1995;182(3):875-884.
25. Long E.O. Regulation of immune response through inhibitory receptors. Annu Rev Immunol. 1999;17:875-904. (Pubitemid 29241142)
26. Lopez-Botet M., et al. Structure and function of the CD94 C-type lectin receptor complex involved in the recognition of HLA class I molecules. Immunol Rev. 1997;155:165-174. (Pubitemid 27076068)
27. Madjd Z., Spendlove I., Pinder S.E., Ellis I.O., Durrant L.G. Total loss of MHC class-I is an independent indicator of good prognosis in breast cancer. Int J Cancer. 2005;117(2):248-255. (Pubitemid 41377445)
28. McGilvray R.W., et al. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res. 2009;15(22):6993-7002.
29. Le Maux Chansac B., et al. NK-cells infiltrating a MHC class-I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK-cell-triggering receptors. J Immunol. 2005;175(9):5790-5798. (Pubitemid 41508063)
30. Della Chiesa M., et al. The tryptophan catabolite Lkynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NKcell function. Blood. 2006;108(13):4118-4125. (Pubitemid 44913283)
31. Castriconi R., et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A. 2003;100(7):4120-4125. (Pubitemid 36418167)
32. Yarbro J.W., Page D.L., Fielding L.P., Partridge E.E., Murphy G.P. American Joint Committee on Cancer prognostic factors consensus conference. Cancer. 1999;86(11):2436-2446. (Pubitemid 30010388)
33. Bryceson Y.T., et al. Functional analysis of human NK-cells by flow cytometry. Methods Mol Biol. 2010;612:335-352.
34. Todd J.H., et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer. 1987;56(4):489-492. (Pubitemid 17146357)
35. Rosenwald A., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(25):1937-1947. (Pubitemid 34651353)
36. Galon J., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-1964. (Pubitemid 44498003)
37. Dighe A.S., Richards E., Old L.J., Schreiber R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity. 1994;1(6):447-456.
38. Kaplan D.H., et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A. 1998;95(13):7556-7561. (Pubitemid 28293291)
39. Garner W.L., Minton J.P., James A.G., Hoffmann C.C. Human breast cancer and impaired NK-cell function. J Surg Oncol. 1983;24(1):64-66 (Pubitemid 13004154)
40. Dewan M.Z., et al. Natural-killer activity of peripheral- blood mononuclear cells in breast cancer patients. Biomed Pharmacother. 2009;63(9):703-706.
41. Pagès F., et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27(35):5944-5951.
42. Takanami I., Takeuchi K., Giga M. The prognostic value of Natural-killer cell infiltration in resected pulmonary adenocarcinoma. J Thorac Cardiovasc Surg. 2001;121(6):1058-1063.
43. Mahmoud S.M., et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949-1955.
44. Costello R.T., et al. Defective expression and function of Natural-killer cell-triggering receptors in patients with acute myeloid leukemia. Blood. 2002;99(10):3661-3667. (Pubitemid 34534536)
45. Lakshmikanth T., et al. NCRs and DNAM-1 mediate NK-cell recognition and lysis of human and mouse melanoma cell lines in-vitro and in-vivo. J Clin Invest. 2009;119(5):1251-1263.
46. Epling-Burnette P.K., et al. Reduced Natural-killer function associated with high-risk myelodysplastic syndrome and reduced expression of activating NK-receptors. Blood. 2007;109(11):4816-4824. (Pubitemid 46827777)
47. Carlsten M., et al. Reduced DNAM-1 expression on bone marrow NK-cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome. Leukemia. 2010;24(9):1607-1616.
48. Bedel R., et al. Novel role for STAT3 in transcriptional regulation of NK-immune cell targeting receptor MICA on cancer cells. Cancer Res. 2011;71(5):1615-1626.
49. Kloess S., et al. IL-2-activated haploidentical NKcells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA. Eur J Immunol. 2010;40(11):3255-3267.
50. Swann J.B., Smyth M.J. Immune surveillance of tumors. J Clin Invest. 2007;117(5):1137-1146. (Pubitemid 46718398)
51. Fauriat C., et al. Deficient expression of NCR in NK-cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood. 2007;109(1):323-330. (Pubitemid 46053073)
52. Flavell R.A., Sanjabi S., Wrzesinski S.H., Licona- Limón P. The polarization of immune cells in the tumor environment by TGF-beta. Nat Rev Immunol. 2010;10(8):554-567.
53. Yang L., Pang Y., Moses H.L. TGF-beta and immune cells: An important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010;31(6):220-227.
54. Toomey D., et al. TGF-beta1 is elevated in breast cancer tissue and regulates nitric oxide production from a number of cellular sources during hypoxia re-oxygenation injury. Br J Biomed Sci. 2001; 58(3):177-183. (Pubitemid 32906906)
55. Arteaga C.L., Hurd S.D., Winnier A.R., Johnson M.D., Fendly B.M., Forbes J.T. Anti-transforming growth factor-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen Natural- killer-cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest. 1993;92(6):2569-2576. (Pubitemid 24006519)
56. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131-142. (Pubitemid 43278296)
57. Christfori G. New signals from the invasive front. Nature. 2006;441(7092):444-450.
58. Brabletz T., Jung A., Spaderna S., Hlubek F., Kirchner T. Migrating cancer stem cells- an integrated concept of malignant tumor progression. Nat Rev Cancer. 2005;5(9):744-749. (Pubitemid 41486367)
59. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818-829. (Pubitemid 351757205)
60. Santisteban M., et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 2009;69(7):2887-2895.
61. Patel S.A., Meyer J.R., Greco S.J., Corcoran K.E., Bryan M., Rameshwar P. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: Role of mesenchymal stem cell-derived TGF-beta. J Immunol. 2010;184(10):5885- 5894.
62. Lin S.Y., et al. The isolation of novel mesenchymal stromal cell chemotactic factors from the conditioned medium of tumor cells. Exp Cell Res. 2008;314(17):3107-3117.
63. Lee J.C., Lee K.M., Kim D.W., Heo D.S. Elevated TGFbeta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol. 2004;172(12):7335-7340. (Pubitemid 38747593)
64. Smyth M.J., Teng M.W., Swann J., Kyparissoudis K., Godfrey D.I., Hayakawa Y. CD4+CD25+ T regulatory cells suppress NK-cell-mediated immunotherapy of cancer. J Immunol. 2006;176(3):1582-1587. (Pubitemid 43134302)
65. Martinet L., Jean C., Dietrich G., Fournié J.J., Poupot R. PGE2 inhibits Natural-killer and gammadelta T-cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling. Biochem Pharmacol. 2010;80(6):838-845.
66. Kundu N., Ma X., Holt D., Goloubeva O., Ostrand- Rosenberg S, Fulton AM. Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res Treat. 2009;117(2):235-242.
67. Madjd Z., et al. Upregulation of MICA on highgrade invasive operable breast carcinoma. Cancer Immun. 2007;7:17.
68. Demotte N., et al. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumorinfiltrating lymphocytes and favors tumor rejection in mice. Cancer Res. 2010;70(19):7476-7488.
69. McGowan P.M., Ryan B.M., Hill A.D., McDermott E.,O'Higgins N., Duffy M.J. ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res. 2007;13(8):2335-2343. (Pubitemid 46698582)
70. Godin-Ethier J., et al. Human activated T-lymphocytes modulate IDO expression in tumors through Th1/ Th2 balance. J Immunol. 2009;183(12):7752- 7760.
71. Guy C.T., Webster M.A., Schaller M., Parsons T.J., Cardiff R.D., Muller W.J. Expression of the neu-protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A. 1992;89(22):10578- 10582.
72. Luci C., et al. Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat Immunol. 2009;10(1):75-82.
73. Castriconi R., et al. Natural-killer cell-mediated killing of freshly isolated neuroblastoma cells: Critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res. 2004;64(24):9180-9184. (Pubitemid 39665534)
74. Cooper M.A., Fehniger T.A., Caligiuri M.A. The biology of human Natural-killer-cell subsets. Trends Immunol. 2001;22(11):633-640.
75. Ferlazzo G., et al. Distinct roles of IL-12 and IL-15 in human Natural-killer cell activation by dendritic- cells from secondary lymphoid organs. Proc Natl Acad Sci U S A. 2004;101(47):16606-16611. (Pubitemid 39557760)
76. Romagnani C., et al. CD56brightCD16- killer Ig-like receptor- NK-cells display longer telomeres and acquire features of CD56dim NK-cells upon activation. J Immunol. 2007;178(8):4947-4955. (Pubitemid 46595277)
77. Freud A.G., Caligiuri M.A. Human Natural-killer cell development. Immunol Rev. 2006;214:56-72.
78. Freud A.G., et al. Evidence for discrete stages of human Natural-killer cell differentiation in vivo. J Exp Med. 2006;203(4):1033-1043.
79. Sun J.C., Beilke J.N., Bezman N.A., Lanier L.L. Homeostatic proliferation generates long-lived Naturalkiller- cells that respond against viral infection. J Exp Med. 2011;208(2):357-368.
80. Joncker N.T., Shifrin N., Delebecque F., Raulet D.H. Mature Natural-killer-cells reset their responsiveness when exposed to an altered MHC environment. J Exp Med. 2010;207(10):2065-2072.
81. Elliott J.M., Wahle J.A., Yokoyama W.M. MHC class-Ideficient Natural-killer-cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J Exp Med. 2010;207(10):2073-2079.
82. Carrega P., et al. Natural-killer-cells infiltrating human non-small-cell lung cancer are enriched in CD56BrightCD16- cells and display an impaired capability to kill tumor cells. Cancer. 2008; 112(4):863-875. (Pubitemid 351240580)
83. Jonsson A.H., Yokoyama W.M. Natural-killer cell tolerance licensing and other mechanisms. Adv Immunol. 2009;101:27-79.
84. Sun J.C. Re-educating Natural-killer-cells. J Exp Med. 2010;207(10):2049-2052.
85. Berg M., et al. Clinical-grade ex vivo-expanded human Natural-killer-cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 2009;11(3):341-355.
86. Romagné F., et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments Natural-killer- mediated killing of tumor cells. Blood. 2009;114(13):2667-2677.
87. Ruggeri L., et al. Donor Natural-killer cell allorecognition of missing-self in haploidentical hematopoietic transplantation for acute myeloid leukemia: Challenging its predictive value. Blood. 2007;110(1):433-440. (Pubitemid 47026866)
88. Kundu N., Walser T.C., Ma X., Fulton A.M. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother. 2005;54(10):981-987. (Pubitemid 41187706)